Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 127 articles:
HTML format
Text format



Single Articles


    March 2017
  1. DESS RT, Sun Y, Matuszak MM, Sun G, et al
    Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Mar 16:JCO2016716142. doi: 10.1200/JCO.2016.71.6142.
    PubMed     Text format     Abstract available


  2. TAMURA T, Kiura K, Seto T, Nakagawa K, et al
    Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
    J Clin Oncol. 2017 Mar 15:JCO2016705749. doi: 10.1200/JCO.2016.70.5749.
    PubMed     Text format     Abstract available


    February 2017
  3. SECKL MJ, Ottensmeier CH, Cullen M, Schmid P, et al
    Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
    J Clin Oncol. 2017 Feb 27:JCO2016697391. doi: 10.1200/JCO.2016.69.7391.
    PubMed     Text format     Abstract available


  4. YANG JC, Ahn MJ, Kim DW, Ramalingam SS, et al
    Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
    J Clin Oncol. 2017 Feb 21:JCO2016703223. doi: 10.1200/JCO.2016.70.3223.
    PubMed     Text format     Abstract available


  5. RUSTHOVEN CG, Palma DA, Senan S, Kavanagh BD, et al
    The Head Start Effect: Will Acute and Delayed Postoperative Mortality Lead to Improved Survival with Stereotactic Body Radiation Therapy for Operable Stage I Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2017 Feb 21:JCO2016720003. doi: 10.1200/JCO.2016.72.0003.
    PubMed     Text format    


  6. NEAL JW, Wakelee HA
    Elusive Target of Angiogenesis in Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Feb 6:JCO2016716084. doi: 10.1200/JCO.2016.71.6084.
    PubMed     Text format    


    January 2017
  7. TISEO M, Boni L, Ambrosio F, Camerini A, et al
    Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
    J Clin Oncol. 2017 Jan 30:JCO2016694844. doi: 10.1200/JCO.2016.69.4844.
    PubMed     Text format     Abstract available


  8. MARCUS MW, Field JK
    Is Bootstrapping Sufficient for Validating a Risk Model for Selection of Participants for a Lung Cancer Screening Program?
    J Clin Oncol. 2017 Jan 23:JCO2016713214. doi: 10.1200/JCO.2016.71.3214.
    PubMed     Text format    


  9. SIMONE CB 2ND
    New Era in Radiation Oncology for Lung Cancer: Recognizing the Importance of Cardiac Irradiation.
    J Clin Oncol. 2017 Jan 23:JCO2016715581. doi: 10.1200/JCO.2016.71.5581.
    PubMed     Text format    


  10. MAGNUSON WJ, Lester-Coll NH, Wu AJ, Yang TJ, et al
    Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naive Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    J Clin Oncol. 2017 Jan 23:JCO2016697144. doi: 10.1200/JCO.2016.69.7144.
    PubMed     Text format     Abstract available


  11. ZHOU L, Deng L, Lu Y
    Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer With Brain Metastasis: Can Up-Front Radiation Therapy Be Deferred or Withheld?
    J Clin Oncol. 2017 Jan 23:JCO2016715706. doi: 10.1200/JCO.2016.71.5706.
    PubMed     Text format    


  12. WANG K, Eblan MJ, Deal AM, Lipner M, et al
    Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
    J Clin Oncol. 2017 Jan 23:JCO2016700229. doi: 10.1200/JCO.2016.70.0229.
    PubMed     Text format     Abstract available


  13. EGUCHI T, Bains S, Lee MC, Tan KS, et al
    Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis.
    J Clin Oncol. 2017;35:281-290.
    PubMed     Text format     Abstract available


  14. MULLER DC, Johansson M, Brennan P
    Lung Cancer Risk Prediction Model Incorporating Lung Function: Development and Validation in the UK Biobank Prospective Cohort Study.
    J Clin Oncol. 2017 Jan 17:JCO2016692467. doi: 10.1200/JCO.2016.69.2467.
    PubMed     Text format     Abstract available


  15. BUNN PA JR
    Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016.
    J Clin Oncol. 2017;35:243-252.
    PubMed     Text format    


  16. BALL D, Mac Manus M, Siva S, Plumridge N, et al
    Routine Use of Intensity-Modulated Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Is Neither Choosing Wisely Nor Personalized Medicine.
    J Clin Oncol. 2017 Jan 9:JCO2016713156.
    PubMed     Text format    


  17. BRADLEY CJ, Yabroff KR, Mariotto AB, Zeruto C, et al
    Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011).
    J Clin Oncol. 2017 Jan 3:JCO2016694166.
    PubMed     Text format     Abstract available


  18. WANG TH, Hu YW, Hu YW
    Benefit of Adjuvant Therapy in Postoperative Early-Stage Small-Cell Lung Cancer: Is There Sufficient Evidence?
    J Clin Oncol. 2017;35:117.
    PubMed     Text format    


  19. CHUN SG, Hu C, Choy H, Komaki RU, et al
    Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
    J Clin Oncol. 2017;35:56-62.
    PubMed     Text format     Abstract available


    December 2016
  20. MOLITORIS JK, Edelman MJ, Regine WF, Feigenberg SJ, et al
    Whole-Brain Radiation in the Treatment of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Dec 28:JCO2016697227.
    PubMed     Text format    


  21. LIANG W, He J, Shen Y, Shen J, et al
    Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry.
    J Clin Oncol. 2016 Dec 28:JCO2016675140.
    PubMed     Text format     Abstract available


  22. OTA A, Gyawali B, Matsuoka A, Ando Y, et al
    Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Dec 5:JCO2016704148.
    PubMed     Text format    


  23. KIM YH
    Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    J Clin Oncol. 2016 Dec 5:JCO2016702472.
    PubMed     Text format    


  24. JANSEN F, Krebber AM, Coupe VM, Cuijpers P, et al
    Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer.
    J Clin Oncol. 2016 Dec 5:JCO2016688739.
    PubMed     Text format     Abstract available


  25. GADGEEL SM, Shaw AT, Govindan R, Gandhi L, et al
    Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016;34:4079-4085.
    PubMed     Text format     Abstract available


  26. WARDAK Z, Choy H
    Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016;34:4064-4065.
    PubMed     Text format    


    November 2016
  27. WIDDER J, Van De Wauwer C, Langendijk JA
    Lobectomy or Sublobectomy for Small Non-Small-Cell Lung Cancer: The Question Remains.
    J Clin Oncol. 2016 Nov 28:JCO2016700872.
    PubMed     Text format    


  28. LEE SM, Falzon M, Blackhall F, Spicer J, et al
    Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
    J Clin Oncol. 2016 Nov 28:JCO2016681841.
    PubMed     Text format     Abstract available


  29. POSTEL-VINAY S, Soria JC
    ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Nov 28:JCO2016705053.
    PubMed     Text format    


  30. ROSENZWEIG KE, Gomez JE
    Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Nov 21:JCO2016699678.
    PubMed     Text format     Abstract available


  31. SULLIVAN DR, Forsberg CW, Ganzini L, Au DH, et al
    Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment.
    J Clin Oncol. 2016;34:3984-3991.
    PubMed     Text format     Abstract available


    September 2016
  32. RIESS JW, Lara PN Jr, Gandara DR
    Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Sep 6. pii: JCO690040.
    PubMed     Text format    


    August 2016
  33. GAJRA A, Loh KP, Hurria A, Muss H, et al
    Comprehensive Geriatric Assessment-Guided Therapy Does Improve Outcomes of Older Patients With Advanced Lung Cancer.
    J Clin Oncol. 2016 Aug 22. pii: JCO675926.
    PubMed     Text format    


  34. SINGH N, Prasad KT
    A Cola to Improve My EGFR TKI Absorption in Metastatic Non-Small-Cell Lung Cancer? No, Thank You, I Prefer Lemonade or Orange Juice Instead.
    J Clin Oncol. 2016 Aug 22. pii: JCO687426.
    PubMed     Text format    


  35. CHENG Y, Murakami H, Yang PC, He J, et al
    Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    J Clin Oncol. 2016 Aug 9. pii: JCO669218.
    PubMed     Text format     Abstract available


  36. PAPADIMITRAKOPOULOU V, Lee JJ, Wistuba II, Tsao AS, et al
    The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Aug 1. pii: JCO660084.
    PubMed     Text format     Abstract available


    July 2016
  37. RECK M, Luft A, Szczesna A, Havel L, et al
    Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jul 25. pii: JCO676601.
    PubMed     Text format     Abstract available


  38. DAMMEIJER F, Lievense LA, Veerman GD, Hoogsteden HC, et al
    The Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2016 Jul 18. pii: JCO663955.
    PubMed     Text format     Abstract available


  39. ROSELL R, Karachaliou N
    Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jul 18. pii: JCO683458.
    PubMed     Text format    


  40. CRINO L, Ahn MJ, De Marinis F, Groen HJ, et al
    Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    J Clin Oncol. 2016 Jul 18. pii: JCO655936.
    PubMed     Text format     Abstract available


  41. GAINOR JF
    Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jul 5. pii: JCO681205.
    PubMed     Text format    


    June 2016
  42. GETTINGER S, Rizvi NA, Chow LQ, Borghaei H, et al
    Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 27. pii: JCO669929.
    PubMed     Text format     Abstract available


  43. YOSHIDA T, Oya Y, Tanaka K, Shimizu J, et al
    Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 27. pii: JCO658732.
    PubMed     Text format     Abstract available


  44. RIZVI NA, Hellmann MD, Brahmer JR, Juergens RA, et al
    Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 27. pii: JCO669861.
    PubMed     Text format     Abstract available


  45. OXNARD GR, Thress KS, Alden RS, Lawrance R, et al
    Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 27. pii: JCO667162.
    PubMed     Text format     Abstract available


  46. RUSTHOVEN CG, Doebele RC
    Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jun 13. pii: JCO672410.
    PubMed     Text format     Abstract available


    May 2016
  47. POTTGEN C, Gauler T, Bellendorf A, Guberina M, et al
    Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectabl
    J Clin Oncol. 2016 May 31. pii: JCO655167.
    PubMed     Text format     Abstract available


  48. KAWAGUCHI T, Koh Y, Ando M, Ito N, et al
    Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study.
    J Clin Oncol. 2016 May 9. pii: JCO642322.
    PubMed     Text format     Abstract available


    April 2016
  49. CHAMBERLAIN MC
    Targetable Lung Cancer Brain Metastases: Improved Outcome.
    J Clin Oncol. 2016 Apr 25. pii: JCO669465.
    PubMed     Text format    


  50. COPUR MS, Ramaekers R, Clark D, Norvell M, et al
    Is It Time to Reconsider Prophylactic Cranial Radiation in Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2016 Apr 25. pii: JCO652974.
    PubMed     Text format    


    March 2016
  51. SOLOMON BJ, Cappuzzo F, Felip E, Blackhall FH, et al
    Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
    J Clin Oncol. 2016 Mar 28. pii: JCO635888.
    PubMed     Text format     Abstract available


  52. PRESLEY CJ, Gross CP, Lilenbaum RC
    Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient.
    J Clin Oncol. 2016 Mar 21. pii: JCO659599.
    PubMed     Text format     Abstract available


  53. BAROT N
    You Have Seen Her Before.
    J Clin Oncol. 2016;34:1012.
    PubMed     Text format    


  54. AHN JS, Park K
    Reply to Y.H. Kim and M. Mishima.
    J Clin Oncol. 2016;34:768.
    PubMed     Text format    


  55. PETERS S
    Emerging Options After Progression During Crizotinib Therapy.
    J Clin Oncol. 2016;34:643-5.
    PubMed     Text format    


    February 2016
  56. MARTIN LW, D'Cunha J, Wang X, Herzan D, et al
    Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance).
    J Clin Oncol. 2016 Feb 29. pii: JCO634543.
    PubMed     Text format     Abstract available


  57. MELOSKY B, Chu Q, Juergens R, Leighl N, et al
    Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
    J Clin Oncol. 2016 Feb 16. pii: JCO638049.
    PubMed     Text format     Abstract available


  58. PIETANZA MC
    Using a Population-Based Analysis to Determine the Management and Treatment of Early-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Feb 16. pii: JCO656462.
    PubMed     Text format    


  59. CORRE R, Greillier L, Le Caer H, Audigier-Valette C, et al
    Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
    J Clin Oncol. 2016 Feb 16. pii: JCO635839.
    PubMed     Text format     Abstract available


  60. AHN MJ
    Reply to E. Giovannetti et al.
    J Clin Oncol. 2016;34:512-3.
    PubMed     Text format    


  61. VAN LEEUWEN RW, Peric R, Hussaarts KG, Kienhuis E, et al
    Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Feb 8. pii: JCO652560.
    PubMed     Text format     Abstract available


  62. BRAMBILLA E, Le Teuff G, Marguet S, Lantuejoul S, et al
    Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Feb 1. pii: JCO630970.
    PubMed     Text format     Abstract available


    January 2016
  63. SENAN S, Brade A, Wang LH, Vansteenkiste J, et al
    PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 25. pii: JCO648824.
    PubMed     Text format     Abstract available


  64. KUIJPERS W, Oldenburg HS, Wouters MW, Aaronson NK, et al
    Feasibility and preliminary efficacy of an interactive portal for lung cancer patients.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  65. RYAN J, Fetrick A, Ganti AK
    Late-stage lung cancer patient preferences about chemotherapy treatment adverse side effects.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available


  66. AWAD MM
    Understanding the Pathway: Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 19. pii: JCO642777.
    PubMed     Text format    


  67. YANG CJ, Chan DY, Speicher PJ, Gulack BC, et al
    Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 19. pii: JCO638171.
    PubMed     Text format     Abstract available


  68. DECATRIS MP, Farrugia D, O'Byrne KJ
    Clinician Perspective on Molecular Profiling of Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 11. pii: JCO652040.
    PubMed     Text format    


  69. KIM YH, Mishima M
    Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Jan 11. pii: JCO639393.
    PubMed     Text format    


  70. BEZJAK A, Temin S, Azzoli CG
    Reply to B. Jeremic et al.
    J Clin Oncol. 2016;34:197-8.
    PubMed     Text format    


  71. AWAD MM, Oxnard GR, Jackman DM, Savukoski DO, et al
    MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
    J Clin Oncol. 2016 Jan 4. pii: JCO634600.
    PubMed     Text format     Abstract available


    December 2015
  72. GIOVANNETTI E, Zucali PA, Rolfo C, Assaraf YG, et al
    Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open.
    J Clin Oncol. 2015 Dec 28. pii: JCO642496.
    PubMed     Text format    


  73. MACBETH F, Noble S, Evans J, Ahmed S, et al
    Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.
    J Clin Oncol. 2015 Dec 23. pii: JCO640268.
    PubMed     Text format     Abstract available


  74. PATEL MI, Wang A, Kapphahn K, Desai M, et al
    Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative.
    J Clin Oncol. 2015 Dec 23. pii: JCO635789.
    PubMed     Text format     Abstract available


  75. DONINGTON JS
    An Additional Step Toward Personalization of Surgical Care for Early-Stage Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2015 Dec 7. pii: JCO647578.
    PubMed     Text format    


  76. AN MW, Han Y, Meyers JP, Bogaerts J, et al
    Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.
    J Clin Oncol. 2015;33:4048-57.
    PubMed     Text format     Abstract available


  77. CURLEY BF
    You've Lived a Good Life.
    J Clin Oncol. 2015;33:4118-9.
    PubMed     Text format    


  78. HURWITZ HI, Uppal N, Wagner SA, Bendell JC, et al
    Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    J Clin Oncol. 2015;33:4039-47.
    PubMed     Text format     Abstract available


    November 2015
  79. SHI W, Dicker AP
    CNS Metastases in Patients With Non-Small-Cell Lung Cancer and ALK Gene Rearrangement.
    J Clin Oncol. 2015 Nov 30. pii: JCO639682.
    PubMed     Text format    


  80. OU SI, Ahn JS, De Petris L, Govindan R, et al
    Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
    J Clin Oncol. 2015 Nov 23. pii: JCO639443.
    PubMed     Text format     Abstract available


  81. JEREMIC B, Cihoric N, Casas F, Gomez-Caamano A, et al
    No Role For Trimodality Therapy and Consolidation Chemotherapy Compared With Concurrent Radiochemotherapy Alone in Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.63.5037.
    PubMed     Text format    


  82. MELOSKY B, Anderson H, Burkes RL, Chu Q, et al
    Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.62.3918.
    PubMed     Text format     Abstract available


  83. BIRKBAK NJ, Hiley CT, Swanton C
    Evolutionary Precision Medicine: A Role for Repeat Epidermal Growth Factor Receptor Analysis in ALK-Rearranged Lung Adenocarcinoma?
    J Clin Oncol. 2015;33:3681-3.
    PubMed     Text format    


  84. CAI W, Lin D, Wu C, Li X, et al
    Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
    J Clin Oncol. 2015;33:3701-9.
    PubMed     Text format     Abstract available


  85. MURPHY C, Schwalb H, Berlangieri S, Eek R, et al
    Intraluminal Superior Vena Cava Metastasis in a Patient With Poorly Differentiated Thyroid Carcinoma.
    J Clin Oncol. 2015;33:e119-21.
    PubMed     Text format    


  86. EBERHARDT WE, Pottgen C, Gauler TC, Friedel G, et al
    Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    J Clin Oncol. 2015 Nov 2. pii: JCO.2015.62.6812.
    PubMed     Text format     Abstract available


  87. MURPHY DR, Wu L, Thomas EJ, Forjuoh SN, et al
    Electronic Trigger-Based Intervention to Reduce Delays in Diagnostic Evaluation for Cancer: A Cluster Randomized Controlled Trial.
    J Clin Oncol. 2015;33:3560-7.
    PubMed     Text format     Abstract available


  88. CHIOU VL, Burotto M
    Pseudoprogression and Immune-Related Response in Solid Tumors.
    J Clin Oncol. 2015;33:3541-3.
    PubMed     Text format    


  89. GRAZIANO P, de Marinis F, Gori B, Gasbarra R, et al
    EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.
    J Clin Oncol. 2015;33:e115-8.
    PubMed     Text format    


    October 2015
  90. BOGART JA, Gajra A
    Limited-Stage Small-Cell Lung Cancer: An Age Limit for Combined Modality Therapy?
    J Clin Oncol. 2015 Oct 26. pii: JCO.2015.64.0888.
    PubMed     Text format    


  91. CORSO CD, Rutter CE, Park HS, Lester-Coll NH, et al
    Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2015 Oct 19. pii: JCO.2015.62.4270.
    PubMed     Text format     Abstract available


  92. JOHUNG KL, Yeh N, Desai NB, Williams TM, et al
    Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
    J Clin Oncol. 2015 Oct 5. pii: JCO.2015.62.0138.
    PubMed     Text format     Abstract available


  93. NOVELLO S
    Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2015 Oct 5. pii: JCO.2015.63.7587.
    PubMed     Text format    


    September 2015
  94. SANTANA-DAVILA R, Devisetty K, Whittle J
    Reply to D.A. Palma et al and A. Addeo et al.
    J Clin Oncol. 2015;33:2929.
    PubMed     Text format    


  95. GILL BS, Flickinger JC, Beriwal S
    Caveat for Immortal Time Bias in Adjuvant Therapy-Related Population-Based Analyses.
    J Clin Oncol. 2015;33:2931.
    PubMed     Text format    


  96. ROBINSON CG, Patel AP, DeWees T, Morgensztern D, et al
    Reply to C. Le Pechoux et al and B.S. Gill et al.
    J Clin Oncol. 2015;33:2932-3.
    PubMed     Text format    


  97. EBERHARDT WE
    Reply to D.A. Palma et al and A. Addeo et al.
    J Clin Oncol. 2015;33:2929-30.
    PubMed     Text format    


  98. GANDARA DR, Lara PN Jr, Mack PC
    Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap.
    J Clin Oncol. 2015;33:2839-40.
    PubMed     Text format    


  99. UJIIE H, Kadota K, Chaft JE, Buitrago D, et al
    Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.
    J Clin Oncol. 2015;33:2877-84.
    PubMed     Text format     Abstract available


  100. RUDIN CM, Ismaila N, Hann CL, Malhotra N, et al
    Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.
    J Clin Oncol. 2015 Sep 8. pii: JCO.2015.63.7918.
    PubMed     Text format     Abstract available


  101. BALDO P, Fornasier G, Francescon S, Ferrarin E, et al
    Toxicities and Adverse Drug Reactions Experienced During Anticancer Treatment: It Is Desirable to Consider the Problem Within the International System of Pharmacovigilance.
    J Clin Oncol. 2015;33:2824-5.
    PubMed     Text format    


  102. PERRONE F, Di Maio M, Gallo C
    Reply to P. Baldo et al.
    J Clin Oncol. 2015;33:2826.
    PubMed     Text format    


  103. THOMAS A, Lopez-Chavez A, Giaccone G
    Reply to A. Stenzinger et al.
    J Clin Oncol. 2015;33:2824.
    PubMed     Text format    


  104. STENZINGER A, Weichert W, Lennerz JK, Klauschen F, et al
    Basket Trials: Just the End of the First Quarter.
    J Clin Oncol. 2015;33:2823-4.
    PubMed     Text format    


    August 2015
  105. KELLY K, Altorki NK, Eberhardt WE, O'Brien ME, et al
    Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
    J Clin Oncol. 2015 Aug 31. pii: JCO.2015.61.8918.
    PubMed     Text format     Abstract available


  106. MASTERS GA, Temin S, Azzoli CG, Giaccone G, et al
    Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2015 Aug 31. pii: JCO.2015.62.1342.
    PubMed     Text format     Abstract available


  107. PELED N, Ilouze M
    Screening for Lung Cancer: What Comes Next?
    J Clin Oncol. 2015 Aug 24. pii: JCO.2015.63.1713.
    PubMed     Text format    


  108. WIKOFF WR, Hanash S, DeFelice B, Miyamoto S, et al
    Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.
    J Clin Oncol. 2015 Aug 17. pii: JCO.2015.61.7779.
    PubMed     Text format     Abstract available


  109. VELUSWAMY RR, Ezer N, Mhango G, Goodman E, et al
    Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: Impact of Histology.
    J Clin Oncol. 2015 Aug 3. pii: JCO.2014.60.6624.
    PubMed     Text format     Abstract available


  110. STEWART EL, Mascaux C, Pham NA, Sakashita S, et al
    Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    J Clin Oncol. 2015;33:2472-80.
    PubMed     Text format     Abstract available


    July 2015
  111. PALMA DA, Senan S, Rodrigues G
    Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III Non-Small-Cell Lung Cancer: Is There an Impact on Radiation Pneumonitis Rates?
    J Clin Oncol. 2015 Jul 27. pii: JCO.2014.60.3845.
    PubMed     Text format    


  112. LE PECHOUX C, Dunant A, Faivre-Finn C, Thomas PA, et al
    Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence.
    J Clin Oncol. 2015 Jul 27. pii: JCO.2015.62.1458.
    PubMed     Text format    


  113. ADDEO A, Comins C
    Optimal Concurrent Chemoradiotherapy Regimen in Non-Small-Cell Lung Cancer: Prospective, Randomized Data Still Required.
    J Clin Oncol. 2015 Jul 27. pii: JCO.2015.61.7332.
    PubMed     Text format    


  114. SCAGLIOTTI G, von Pawel J, Novello S, Ramlau R, et al
    Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2015 Jul 13. pii: JCO.2014.60.7317.
    PubMed     Text format     Abstract available


  115. CHEN HY, Yu SL, Ho BC, Su KY, et al
    R331W Missense Mutation of Oncogene YAP1 Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability.
    J Clin Oncol. 2015;33:2303-10.
    PubMed     Text format     Abstract available


  116. AHN JS, Ahn YC, Kim JH, Lee CG, et al
    Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
    J Clin Oncol. 2015 Jul 6. pii: JCO.2014.60.0130.
    PubMed     Text format     Abstract available


    June 2015
  117. SUN JM, Ahn JS, Jung SH, Sun J, et al
    Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylated Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.
    J Clin Oncol. 2015 Jun 29. pii: JCO.2014.59.9324.
    PubMed     Text format     Abstract available


  118. WANG EH, Corso CD, Rutter CE, Park HS, et al
    Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2015 Jun 22. pii: JCO.2015.61.1517.
    PubMed     Text format     Abstract available


  119. AWAD MM, Hammerman PS
    Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.
    J Clin Oncol. 2015;33:1993-4.
    PubMed     Text format    


  120. PAN D
    YAPing Hippo Forecasts a New Target for Lung Cancer Prevention and Treatment.
    J Clin Oncol. 2015 Jun 8. pii: JCO.2015.61.2093.
    PubMed     Text format    


    May 2015
  121. ZHOU C, Wu YL, Chen G, Liu X, et al
    BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2015 May 26. pii: JCO.2014.59.4424.
    PubMed     Text format     Abstract available


  122. GIBNEY GT, Atkins MB
    Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
    J Clin Oncol. 2015 May 11. pii: JCO.2014.60.1807.
    PubMed     Text format    


    April 2015
  123. HOSKINS PJ, Fung-Kee-Fung M, Miller D, Gotlieb W, et al
    Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes-The Example of Bevacizumab in Epithelial Ovarian Cancer.
    J Clin Oncol. 2015 Apr 6. pii: JCO.2014.58.3690.
    PubMed     Text format    


    March 2015
  124. REDIG AJ, Janne PA
    Basket trials and the evolution of clinical trial design in an era of genomic medicine.
    J Clin Oncol. 2015;33:975-7.
    PubMed     Text format    


  125. MAZIERES J, Zalcman G, Crino L, Biondani P, et al
    Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    J Clin Oncol. 2015;33:992-9.
    PubMed     Text format     Abstract available


  126. LOPEZ-CHAVEZ A, Thomas A, Rajan A, Raffeld M, et al
    Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
    J Clin Oncol. 2015;33:1000-7.
    PubMed     Text format     Abstract available


    March 2014
  127. GODBERT Y, Henriques de Figueiredo B, Bonichon F, Chibon F, et al
    Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
    J Clin Oncol. 2014.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: